Company Description
Using novel high throughput genome engineering and screening technologies in a design loop with computational tools, 64x Bio is developing new ways of generating highly optimized and otherwise unattainable mammalian cell lines for design and manufacture of next generation therapeutics, with a specific focus on those used for cell and gene therapies. Our platform technologies enable pharmaceutical and biotechnology companies, as well as CDMOs to bring cell and gene therapies to patients more effectively.
Significant Investors
First Round Capital, Lifeforce Capital, Northpond Ventures, Future Ventures, Alix Ventures, Fifty Years, SV Angel, BoxGroup, Refactor Capital
